ISSCR News
The ISSCR Provides Comments on FDA’s Draft Guidance for Potency Assurance for Cellular and Gene Therapy Products
On 5 March 2023, the ISSCR submitted comments on the Food and Drug Administration’s draft guidance for Potency Assurance for Cellular and Gene Therapy (CGT) Products. ISSCR appreciates FDA’s commitment to assuring the potency of human CGT products at all stages of the product lifecycle. This guidance from the FDA will help our members, who are at the forefront of research and innovation, in their work.
The ISSCR Signs On to the Coalition for Health Funding’s Non-Defense Discretionary (NDD) United Campaign
On 3 January 2024, the ISSCR signed on to the NDD United campaign urging Congress to complete the FY 2024 appropriations process and adopt the bipartisan Senate funding framework as a starting point for final negotiations.
The ISSCR Responds to Ranking Member Cassidy’s Request for Information on NIH Reform
On 27 October 2023, the ISSCR submitted comments to Senate Health, Education, Labor and Pensions Committee Ranking Member Bill Cassidy’s Request for Information on reforming the National Institutes of Health (NIH).
The ISSCR Provides Comments on FNIH’s Accelerating Medicines Partnership Cell-Based Therapy Initiative
On 25 September 2023, the ISSCR submitted comments in response to the Foundation for National Institutes of Health’s (FNIH) Request for Information on Cell-Based Therapies for use in developing an Accelerating Medicines Partnership (AMP) Cell-Based Therapy Consortium.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .